Loading…
Based on limited metadata available, this FDA Warning Letter issued to CoinRx in August 2018 addresses an unspecified product categorized as "Other," indicating it falls outside standard FDA product classifications. Without access to the full letter text or a documented subject line, the specific nature of the violations cannot be determined with certainty. The issuing office information is unavailable, which limits clarity on the regulatory division involved and the precise product category under inspection. Additional documentation would be needed to provide specific details about the compliance issues cited.